CD30 expression is a defining feature of anaplastic large-cell lymphoma (sALCL); brentuxi...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-CD30-ALCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-ALCL |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-CD30-IHC |
|---|---|
| Variant | CD30 expression — universal (~100%) in systemic anaplastic large-cell lymphoma (ALK-positive and ALK-negative) |
| Disease | DIS-ALCL |
| ESCAT tier | IA |
| Recommended combinations | BV + CHP — 1L sALCL per SRC-NCCN-BCELL-2025, SRC-ESMO-PTCL-2024, BV monotherapy — R/R sALCL salvage per SRC-NCCN-BCELL-2025, consolidative autologous HCT in CR1 (high-risk subgroups per SRC-NCCN-BCELL-2025) |
| Contraindicated monotherapy | BV + bleomycin (pulmonary toxicity contraindication), CHOP without BV in CD30+ PTCL with adequate CD30 expression (inferior per SRC-ECHELON-2) |
| Evidence summary | CD30 expression is a defining feature of anaplastic large-cell lymphoma (sALCL); brentuximab vedotin (BV) targets CD30 with an auristatin payload. 1L sALCL: BV + CHP (cyclophosphamide / doxorubicin / prednisone, replacing vincristine) is preferred over CHOP per ECHELON-2 (Horwitz Lancet 2019 — mPFS 48 vs 21 mo, HR 0.71; OS HR 0.66) per SRC-NCCN-BCELL-2025, SRC-ESMO-PTCL-2024. R/R sALCL: BV monotherapy was the basis of FDA accelerated approval (Pro JCO 2012 — ORR 86%, CR 57%) and is preferred salvage. Pediatric ALCL: AHOD1331 supports BV + AVEPC. |
Notes
ESCAT IA / OncoKB Level 1. Existing BMA-ALK-FUSION-ALCL covers ALK- rearranged subset (where crizotinib R/R has different role). For sALCL, BV+CHP is genotype-agnostic 1L (covers ALK-positive and ALK- negative). ECHELON-2 enrolled CD30+ PTCL with ≥10% expression — that threshold is the standard inclusion gate. Source-gap: SRC-ECHELON-2, SRC-AHOD1331 not yet ingested.
Used By
No reverse references found in the YAML corpus.